- Merck announced positive new findings from the second RSV season of its phase 3 SMART trial for clesrovimab (Enflonsia), a treatment aimed at high-risk young children. According to ContagionLive, these results are a significant development.
- The positive data from Merck's trial suggests potential advancements in protecting vulnerable pediatric populations against RSV.
- GSK unveiled new real-world effectiveness data for its RSV vaccine, Arexvy, at the RSVVW'26 conference in Rome. ContagionLive reported on this presentation.
- The release of Arexvy's real-world data by GSK at a prominent conference like RSVVW'26 highlights ongoing efforts to evaluate and enhance RSV vaccine efficacy.
- The FDA has reversed its earlier decision and will now review Moderna's investigational influenza vaccine, mRNA-1010. This move, as noted by ContagionLive, represents a crucial step for Moderna's vaccine candidate.
Top Infectious Disease News: Feb 15-21
Major advancements in infectious disease prevention are on the horizon, as Merck unveiled positive Phase 3 trial results for its RSV treatment, clesrovimab, aimed at protecting high-risk young children, and GSK presented new real-world effectiveness data for its Arexvy vaccine. Adding to these developments, the FDA has reversed its decision and will now review Moderna's investigational mRNA-1010 influenza vaccine, signaling a crucial step for its potential approval.
Sources
1
Editorial Process: This article was drafted using AI-assisted research and thoroughly reviewed by human editors for accuracy, tone, and clarity. All content undergoes human editorial review to ensure accuracy and neutrality.
Reviewed by: Bridgette Jacobs
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
